HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pyroglutamylleucine

RN given refers to L-leucine; RN for cpd without isomeric designation not in Chemline 7/84

Also Known As:

pGlu-Leu; pyroGlu-Leu

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sato, Kenji: 5 articles (01/2019 - 07/2013)
2.	Kiyono, Tamami: 4 articles (01/2015 - 07/2013)
3.	Nakamura, Yasushi: 3 articles (01/2019 - 07/2013)
4.	Park, Eun Young: 3 articles (11/2013 - 07/2013)
5.	Ikeda, Kaori: 1 article (01/2019)
6.	Inagaki, Nobuya: 1 article (01/2019)
7.	Kojima, Yumi: 1 article (01/2019)
8.	Matsumura, Yasuki: 1 article (01/2019)
9.	Shirako, Saki: 1 article (01/2019)
10.	Tomari, Naohiro: 1 article (01/2019)

Related Diseases

1.	Inflammation (Inflammations) 01/30/2015 - "We hypothesized that pyroGlu-Leu inhibits the induction of iNOS gene expression, resulting in the attenuation of hepatic inflammation. " 01/30/2015 - "We examined proinflammatory cytokine-stimulated hepatocytes as a simple "in vitro inflammation model" to determine liver protective effects of pyroGlu-Leu and its mechanisms of action. "
2.	Colitis 09/18/2013 - "The objective of present study is to elucidate improvement of colitis by oral administration of pyroGlu-Leu in an animal model. " 11/27/2013 - "PyroGlu-Leu has been demonstrated to attenuate hepatitis and colitis in animal models. " 09/18/2013 - "Acute colitis was induced by dextran sulfate sodium (DSS), and various concentrations of pyroGlu-Leu were administrated by oral gavage for 7 days. " 01/01/2019 - "Our previous study demonstrated that the oral administration of pyroGlu-Leu (0.1 mg/kg body weight) attenuates dysbiosis in mice with experimental colitis. "
3.	Body Weight (Weight, Body) 01/01/2019 - "Oral administration of pyroGlu-Leu (1 mg/kg body weight) significantly attenuated high fat diet-induced dysbiosis. " 01/01/2019 - "Our previous study demonstrated that the oral administration of pyroGlu-Leu (0.1 mg/kg body weight) attenuates dysbiosis in mice with experimental colitis. " 07/03/2013 - "Ingestion of pyroGlu-Leu at 20 mg/kg body weight significantly decreased serum aspartate and alanine aminotransferases to approximately 30% and 20% of those values of the vehicle group, respectively, which were near the normal levels. "
4.	Dysbiosis 01/01/2019 - "The objective of this study was to elucidate why such a low dose of pyroGlu-Leu attenuates dysbiosis in different animal models. " 01/01/2019 - "Here, we report that orally administered pyroGlu-Leu attenuates dysbiosis by increasing in the host antimicrobial peptide, rattusin." 01/01/2019 - "Oral administration of pyroGlu-Leu (1 mg/kg body weight) significantly attenuated high fat diet-induced dysbiosis. " 01/01/2019 - "Our previous study demonstrated that the oral administration of pyroGlu-Leu (0.1 mg/kg body weight) attenuates dysbiosis in mice with experimental colitis. "
5.	Hepatitis 11/27/2013 - "PyroGlu-Leu has been demonstrated to attenuate hepatitis and colitis in animal models. " 07/03/2013 - "A hepatoprotective peptide, pyroglutamyl leucine (pyroGlu-Leu), was identified in wheat gluten hydrolysate through an in vivo activity-guided fractionation approach based on D-galactosamine-induced acute hepatitis in rats and fractionation of peptides with large-scale preparative ampholine-free isoelectric focusing. "

Related Drugs and Biologics

1.	Cytokines
2.	Peptides (Polypeptides)
3.	Leucine (L-Leucine)
4.	Glutens (Glutelin)
5.	Dextran Sulfate
6.	Galactosamine
7.	Aspartic Acid (Aspartate)
8.	Transaminases (Aminotransferases)
9.	Alanine (L-Alanine)
10.	Antimicrobial Peptides

Related Therapies and Procedures

1.	Oral Administration